Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study

The Lancet

Volumn 374, Issue 9697, 2009, Pages 1262-1270

  Marsden, John ^a   Eastwood, Brian ^b   Bradbury, Colin ^b   Dale Perera, Annette ^b   Farrell, Michael ^a   Hammond, Paul ^b   Knight, Jonathan ^b   Randhawa, Kulvir ^b   Wright, Craig ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b National Treatment Agency for Substance Misuse   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; COCAINE; DIAMORPHINE; METHADONE;

ADULT; ARTICLE; COCAINE DEPENDENCE; COGNITIVE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GROUP THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHINE ADDICTION; MOTIVATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSOCIAL CARE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 70349783783     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61420-3     Document Type: Article

References (35)

1. WHO. International statistical classification of disease and health-related problems (ICD-10) (1993), World Health Organization, Geneva
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. (1994), American Psychiatric Association, Washington, DC
3. McLellan A.T., Lewis D.C., O'Brien C.P., and Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284 (2000) 1689-1695
4. Hser Y.I., Hoffman V., Grella C.E., and Anglin M.D. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 58 (2001) 503-508
5. Nutt D., King L.A., Saulsbury W., and Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369 (2007) 1047-1053
6. Hay G., Gannon M., MacDougall J., Millar T., Eastwood C., and McKeganey N. Local and national estimates of the prevalence of opioid use and/or crack cocaine use (2004/05). In: Singleton N, Murray R, Tinsley L, eds. Measuring different aspects of problem drug use: methodological developments (2nd edn). Home Office online report 16/06. http://www.homeoffice.gov.uk/rds/pdfs06/rdsolr1606.pdf (accessed July 29, 2009).
7. Hay G., Gannon M., MacDougall J., et al. National and regional estimates of the prevalence of opiate use and/or crack cocaine use 2006/07: a summary of key findings. Home Office research report 9: summary. http://www.homeoffice.gov.uk/rds/pdfs08/horr09.pdf (accessed July 29, 2009).
8. Statistics from the National Drug Treatment Monitoring System (April 1, 2007-March 31, 2008). http://www.nta.nhs.uk/areas/facts_and_figures/0708/docs/ndtms_annual_report_2007_08_011008.pdf (accessed July 29, 2009).
9. Grella C.E., Anglin M.D., and Wugalter S.E. Cocaine and crack use and HIV risk behaviours among high-risk methadone maintenance clients. Drug Alcohol Depend 37 (1995) 15-21
10. Williamson A., Darke S., Ross J., and Teesson M. The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. Drug Alcohol Depend 81 (2006) 293-300
11. Gossop M., Marsden J., Stewart D., and Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction 98 (2003) 291-303
12. Marsden J., Farrell M., Bradbury C., et al. Development of the Treatment Outcomes Profile. Addiction 103 (2008) 1450-1460
13. HM Government. Drugs: protecting families and communities. The 2008 drug strategy. http://drugs.homeoffice.gov.uk/publication-search/drug-strategy/drug-strategy-2008 (accessed July 29, 2009).
14. Department of Health (England) and the devolved administrations (2007). Drug misuse and dependence: UK guidelines on clinical management (2007), Department of Health (England), the Scottish Government, Welsh Assembly Government, and Northern Ireland Executive, London
15. National Institute for Health and Clinical Excellence. Drug misuse: opioid detoxification (NICE clinical guideline 52). http://www.nice.org.uk/Guidance/CG52 (accessed July 29, 2009).
16. National Institute for Health and Clinical Excellence. Drug misuse: psychosocial interventions (NICE clinical guideline 51). http://www.nice.org.uk/Guidance/CG51 (accessed July 29, 2009).
17. National Treatment Agency for Substance Misuse. Models of care for adult drug misusers: update 2006. http://www.nta.nhs.uk/publications/documents/nta_modelsofcare_update_2006_moc3.pdf (accessed July 29, 2009).
18. National Treatment Agency for Substance Misuse. Care planning practice guide. http://www.nta.nhs.uk/publications/documents/nta_care_planning_practice_guide_2006_cpg1.pdf (accessed July 29, 2009).
19. Del Boca F.K., and Noll J.A. Truth or consequences: the validity of self-report data in health services research on addictions. Addiction 95 suppl 3 (2000) S347-S360
20. Fals-Stewart W., O'Farrell T.J., Freitas T.T., McFarlin S.K., and Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 68 (2000) 134-144
21. Cone E.J., Presley L., Lehrer M., et al. Oral fluid testing for drugs of abuse: positive prevalence rates by intercept immunoassay screening and GC-MS-MS confirmation and suggested cut-off concentrations. J Anal Toxicol 26 (2002) 541-546
22. Kraemer H.C., and Thiemann S. How many subjects? Statistical power analysis in research (1987), Sage, Newbury Park, CA
23. Jacobson N.S., and Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59 (1991) 12-19
24. National Treatment Agency for Substance Misuse. Black and minority ethnic communities in England: a review of the literature on drug use and related service provision. http://www.nta.nhs.uk/areas/diversity/docs/BME_Literature_review.pdf c(accessed July 29, 2009).
25. Roberts L.J., Neal D.J., Kivlahan D.R., Baer J.S., and Marlatt G.A. Individual drinking changes following a brief intervention among college students: clinical significance in an indicated preventive context. J Consult Clin Psychol 68 (2000) 500-505
26. Cisler R.A., Kowalchuk R.K., Saunders S.M., Zweben A., and Trinh H.Q. Applying clinical significance methodology to alcoholism treatment trials: determining recovery outcome status with individual-and population-based measures. Alcohol Clin Exp Res 29 (2005) 1991-2000
27. National Institute on Drug Abuse. Principles of drug addiction treatment: a research-based guide (2nd edn). NIH publication number 09-4180. http://www.nida.nih.gov/PDF/PODAT/PODAT.pdf (accessed July 29, 2009).
28. McCance-Katz EF, Rainey PM, Moody DE. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am J Addict (in press).
29. Moos R.H., and Moos B.S. The staff workplace and the quality and outcome of substance abuse treatment. J Stud on Alcohol 59 (1998) 43-51
30. Farrell M., and Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 103 (2008) 251-255
31. Caplehorn J.R.M., and Drummer O.H. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 170 (1999) 104-109
32. Umbricht A., Huestis M.A., Cone E., and Preston K.L. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol 24 (2004) 479-487
33. Bell J., Trinh L., Butler B., Randall D., and Rubin G. Comparing retention in treatment and mortality in people after initial entry starting on a methadone maintenance program. Am J Forensic Med Pathol 13 (1992) 346-350
34. Teesson M., Ross J., Darke S., et al. One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 83 (2006) 174-180
35. McLellan A.T. Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction 97 (2002) 249-252